EP2714908B1 - Immunostimulatory oligodeoxynucleotides - Google Patents
Immunostimulatory oligodeoxynucleotides Download PDFInfo
- Publication number
- EP2714908B1 EP2714908B1 EP12726042.0A EP12726042A EP2714908B1 EP 2714908 B1 EP2714908 B1 EP 2714908B1 EP 12726042 A EP12726042 A EP 12726042A EP 2714908 B1 EP2714908 B1 EP 2714908B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- virus
- cpg
- oligodeoxynucleotide
- antigen component
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940046166 oligodeoxynucleotide Drugs 0.000 title claims description 55
- 230000003308 immunostimulating effect Effects 0.000 title claims description 32
- 239000000427 antigen Substances 0.000 claims description 38
- 108091007433 antigens Proteins 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 229960005486 vaccine Drugs 0.000 claims description 28
- 241000287828 Gallus gallus Species 0.000 claims description 21
- 230000002163 immunogen Effects 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 11
- 150000004713 phosphodiesters Chemical class 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 244000144977 poultry Species 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 3
- 241001516406 Avian orthoreovirus Species 0.000 claims description 2
- 241000606767 Avibacterium paragallinarum Species 0.000 claims description 2
- 208000027312 Bursal disease Diseases 0.000 claims description 2
- 241000886677 Duck adenovirus 1 Species 0.000 claims description 2
- 241000223924 Eimeria Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 2
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 claims description 2
- 241000204022 Mycoplasma gallisepticum Species 0.000 claims description 2
- 241000202942 Mycoplasma synoviae Species 0.000 claims description 2
- 241001135620 Ornithobacterium rhinotracheale Species 0.000 claims description 2
- 241000606856 Pasteurella multocida Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241001223089 Tremovirus A Species 0.000 claims description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 229940051027 pasteurella multocida Drugs 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 59
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 42
- 102000053602 DNA Human genes 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 41
- 239000013612 plasmid Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 235000013330 chicken meat Nutrition 0.000 description 19
- 238000001514 detection method Methods 0.000 description 17
- 108700008625 Reporter Genes Proteins 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 12
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 9
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000001994 activation Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000002689 Toll-like receptor Human genes 0.000 description 6
- 108020000411 Toll-like receptor Proteins 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 5
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 4
- 108700038332 Histone deacetylase 11 Proteins 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000012215 gene cloning Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000012646 vaccine adjuvant Substances 0.000 description 3
- 229940124931 vaccine adjuvant Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical class O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 102000007578 Interferon Regulatory Factor-3 Human genes 0.000 description 2
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 1
- QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical class NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 0 C1CC=C*C1 Chemical compound C1CC=C*C1 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- -1 aminohexyl- Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- OFBPGACXRPVDQW-UHFFFAOYSA-N thiirane 1,1-dioxide Chemical group O=S1(=O)CC1 OFBPGACXRPVDQW-UHFFFAOYSA-N 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical class O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Definitions
- the present invention relates to vaccines comprising immunostimulatory oligodeoxynucleotides and/or vectors comprising these oligodeoxynucleotides.
- WO2004/005476 discloses various CpG motifs for therapeutic use in mammals.
- WO2012/089800 discloses CpG motifs and their application in TLR interaction.
- CpG ODNs have also been described and discussed as immunostimulatory agents and vaccine adjuvants in veterinary applications, particularly in bovines, pigs, sheep, dogs, chicken and fish (Babiuk et al. 2003, Carrington and Secombes 2006, Griebel et al. 2005, Mutwiri et al. 2003, Singh and O'Hagan 2003, Werling and Jungi 2003).
- TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides (Brownlie et al., 2009).
- an "immunostimulatory non-methylated oligodeoxynucleotide” refers to an oligodeoxynucleotide, which contains a non-methylated cytidine-phosphate-guanosine di-nucleotide sequence that stimulates the initiation of signaling cascades leading to activation of transcription factors such as NF- ⁇ B or Interferon Regulatory Factor 3 (IRF3). It is this activation that in turn results in the expression of inflammatory cytokines and other cellular activation events.
- NF- ⁇ B binding sites and gene expression influenced by NF- ⁇ B are i.a. described by Schindler and Baichwal (1994).
- oligodeoxynucleotide means a short nucleic acid polymer of deoxynucleotides; i.e. a molecule comprising a multitude of deoxyriboses, linked to a phosphate group and to an exchangeable organic base.
- Such an organic base is a substituted pyrimidine or a substituted purine. Examples are cytosine and thymine respectively adenine and guanine.
- the oligonucleotides according to the invention may comprise modifications.
- modifications are e.g. modifications in the phosphodiester internucleoside bridge located at the 3' and/or 5' end of a nucleoside.
- modifications relate i.a. to the replacement of a phosphodiester by e.g. a phosphorothioate or a phosphorodithioate.
- modifications that concern the replacement of a natural nucleoside base by a non-natural nucleoside base such as inosine, 5-fluorocytosine, 7-deaza-7-substituted guanine, 7-deaza-8-substituted guanine , 2-thiouracil, dihydrouracil, 5-bromo-cytosine, 6-substituted cytosines, N4-substituted cytosines,
- the structure 5' ⁇ T C G T C G ⁇ n 3' carrying the CpG motif represents the active immunostimulating moiety of an ODN according to the invention. Therefore, the present invention provides immunostimulatory oligodeoxynucleotides that comprise this so-called "backbone”.
- the backbone of an oligodeoxynucleotide according to the invention the structure 5' ⁇ T C G T C G ⁇ n 3' must be present at least two, preferably three times. Therefore, n should be at least two. It was also found that the activity of the oligodeoxynucleotides increases when n increases. This effect is leveling when n increases. Basically, the number n of the backbone structure should therefore be at least 2.
- the range of n is 3 ⁇ n ⁇ 100, merely because of the fact that the longer the synthetic sequence the more difficult it is to make. In practice preferably the range of n is 3 ⁇ n ⁇ 18. More preferably, the range of n is 4 ⁇ n ⁇ 18, even more preferably the range of n is 5 ⁇ n ⁇ 18, still even more preferably the range of n is 6 ⁇ n ⁇ 18.
- CpG ODN's for use in the invention was made possible i.a. by using a more selective detection system than the systems currently in use for the detection of NF- ⁇ B activation. Brownlie at al. (2009) describe an NF- ⁇ B luciferase based reporter system. Other systems are e.g. based upon IL-8 transcript measurement or cytokine secretion or the detection of NO secretion.
- SEAP secreted alkaline phosphatase based detection system
- SEAP is a reporter enzyme in mammalian systems (Yang et al., 1997). This system turned out to be surprisingly sensitive and in addition surprisingly provides a close correlation between the in vitro and in vivo activities of the CpG ODN's tested.
- the SEAP system was used with para -nitrophenylphosphate (pNPP) as a substrate.
- x should preferably be at least 3, but increasing numbers of G's up to 20 G's improve the activity of the CpG ODN. Therefore more preferably, x is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 in that increasing order of preference.
- the disclosure also describes oligodeoxynucleotides wherein the 5' [G] z and the 3' [G] z nucleotides have a phosphorothioate binding and the other nucleotides have a phosphodiester binding.
- CpG oligodeoxynucleotides are active in nanomolar amounts, both in the in vitro test system and in vivo.
- the CpG oligodeoxynucleotides according to the invention are even active in picomolar (sub-nanomolar) amounts; their EC50 is below 1 nM.
- the half-maximal effective concentration (EC50) of an oligodeoxynucleotide is the amount of oligodeoxynucleotide that is necessary to induce an amount of the reporter enzyme SEAP (that produces the colored product absorbing at 405 nm) in the reporter cells (HEK293-pNifty2-chickenTLR21 or HD11-pNifTy2Hyg) that gives a half-maximal enzymatic reaction rate. If the EC50 of an oligodeoxynucleotide is below 1 nM in these cells, it is considered to be active in picomolar (sub-nanomolar) amounts.
- Mere examples of such components are e.g. digoxigenin, aminohexyl-, Texas red and biotin.
- Preferred carriers or haptens are 3'- and 5'-labeled Texas red and 5'-labeled digoxigenin.
- the linkage of oligodeoxynucleotides to haptens/carriers is well-known in the art.
- a vaccine comprising a vector comprising an immunostimulatory non-methylated oligodeoxynucleotide as described.
- a vector can be a nucleic acid molecule such as a plasmid, a virus, a bacteriophage or any other vector used in molecular biology.
- a vector comprising an immunostimulatory non-methylated oligodeoxynucleotide can e.g. be a DNA molecule such as a plasmid that can be multiplied in bacteria, into which an immunostimulatory non-methylated oligodeoxynucleotide according to the invention has been cloned.
- Such a plasmid preferably has an active origin of replication, causing high numbers of the plasmid to be present in the host.
- Growing such bacteria on a large scale followed by isolation of the plasmids provides an alternative for the synthetic production of the immunostimulatory non-methylated oligodeoxynucleotide according to the invention.
- One of the aims of the present invention is to provide new CpG ODN's that can be used as successful immunostimulating components in vaccines that prevent or combat infectious disease together with an antigen component or genetic information encoding an antigen component, and a pharmaceutically acceptable carrier.
- antigen component refers to a composition of matter that comprises at least one epitope that can induce, stimulate or enhance an immune response when administered to a human or an animal.
- the antigen component may be any kind of antigen component but preferably is derived from a micro-organism or virus that in its wild-type form is pathogenic to humans or animals.
- the antigen component can be the whole pathogen, preferably in an inactivated or attenuated form, an extract of the pathogen or an immunogenic protein of the pathogen.
- the antigen component is an immunogenic protein of the pathogen
- that immunogenic protein is preferably expressed in and recovered from in vitro cultured cells.
- the invetion relates to a vaccine for preventing or combating infectious disease characterised in that said vaccine comprises an immunostimulating amount of an oligodeoxynucleotide according to the invention and/or a vector according to the invention, an immunogenic amount of an antigen component or genetic information encoding an antigen component, and a pharmaceutically acceptable carrier.
- the immunostimulating amount of the oligodeoxynucleotide and the immunogenic amount of the antigen component are strongly interrelated. It is one of the merits of the present invention that the presence of the oligodeoxynucleotide according to the invention can lower the amount of antigen component that is necessary to prevent or combat infectious disease.
- the amount of antigen component that is necessary to prevent or combat infectious disease is referred to as the immunogenic amount of the antigen component.
- An immunostimulating amount of the oligodeoxynucleotide is the amount that is capable of decreasing the immunogenic amount of the antigen component, i.e. the amount of the antigen component that is necessary to prevent or combat an infectious disease.
- the vaccine comprises genetic information encoding an antigen component
- the amount of antigen component expressed by this genetic information should be enough to prevent or combat infectious disease, i.e.; it must be an immunogenic amount.
- non-methylated oligodeoxynucleotides according to the invention are immunostimulatory, means that they enhance the immunological efficacy of antigen components in vaccines. For that reason, vaccines according to the invention will in many cases comprise less of the antigen component or the genetic information encoding the antigen component than would be the case if no oligodeoxynucleotides according to the invention would be present.
- an antigen component as such without the addition of immunostimulatory oligonucleotides, may have such low immunogenic properties that high amounts must be given anyway, albeit without reaching the desired immunogenic level.
- the antigen component can be given in the usual high concentration, however now together with an oligodeoxynucleotide according to the invention in order to so obtain the desired level of immunogenicity.
- the amount of the antigen component or the genetic information encoding the antigen component to be administered with a oligonucleotide according to the invention would as a rule of thumb be equal or below the amount given in the absence of the oligonucleotide.
- the skilled person involved in the manufacturing of a specific vaccines would know that amount for that specific vaccine.
- the Examples give e.g. ample guidance for the amount of antigen components to be used, e.g. in three different inactivated viral vaccines: Newcastle disease virus vaccine, Infectious Bronchitis virus vaccine and Turkey Rhinotracheitis vaccine.
- the amount of the oligodeoxynucleotide according to the invention that needs to be administered together with the antigen component or the genetic information encoding the antigen component depends both on the selected oligodeoxynucleotide and the antigen component.
- a very suitable amount of oligodeoxynucleotide according to the invention would usually vary between 1 and 100 nanomol. Very good in vivo results have e.g. been obtained with 1-10 ⁇ g of oligodeoxynucleotides according to the invention with an average length of 30 deoxynucleotides that were shown to be active in in vitro tests in the nanomolar range.
- an oligodeoxynucleotide is chosen from the group of oligodeoxynucleotides that are active in the picomolar range, the skilled person would realise that amounts below, possibly far below, 1 nanomol, i.e. picomolar amounts, would be worth testing before testing nanomolar amounts.
- Vaccines according to the invention comprise a pharmaceutically acceptable carrier.
- the nature of this carrier depends i.a. upon the route of administration. If the administration route is through the oral or intranasal route, the carrier could be as simple as sterile water, a physiological salt solution or a buffer. If injection is the preferred route, the carrier should preferably be isotonic and have pH restrictions that make it suitable for injection. Such carriers however are extensively known in the art.
- Vaccines according to the invention may, in addition to the antigen component or the genetic information encoding the antigen component, and an oligodeoxynucleotide according to the invention, comprise an adjuvant.
- Adjuvants in general are substances that boost the immune response of the host in a non-specific manner.
- adjuvants are known in the art to be suitable, such as Freund's Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers and poly-anions such as dextran sulphate, carbopol and pyran, alum hydroxide. Also frequently used are alum phosphate, saponins, vegetable oils such as tocopherol and mineral oils.
- Very efficient adjuvants are oil-in-water emulsions and especially water-in-oil emulsions, further also referred to as are oil-in-water adjuvants and water-in-oil adjuvants. Such emulsions are well-known in the art.
- the vaccine comprises a water-in-oil adjuvant.
- the antigen component is, or is derived from a virus or micro-organism that in its wild-type form is pathogenic to poultry.
- said virus or micro-organism is selected from the group consisting of Infectious Bronchitis virus, Newcastle Disease virus, Infectious Bursal Disease (Gumboro), Chicken Anaemia agent, Avian Reovirus, Mycoplasma gallisepticum, Turkey Rhinotracheitis virus, Haemophilus paragallinarum (Coryza), Chicken Poxvirus, Avian Encephalomyelitis virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, Eimeria species, Ornithobacterium rhinotracheale, Pasteurella multocida, Mycoplasma synoviae, Salmonella species and Escherichia coli.
- the disclosure also describes an immunostimulatory non-methylated oligodeoxynucleotide for use as a medicament.
- the present invention relates to vaccines comprising an immunostimulatory non-methylated oligodeoxynucleotide according for use in preventing or combating infectious disease in poultry
- stable maintenance of a plasmid is obtained by growing the cells under the pressure of one or more selective agents, such as antibiotics for which a resistance gene is present on the plasmid. Loss of the plasmid would then cause the cell that lost the plasmid to die. Remaining viable cells would still harbour the plasmid.
- Still another embodiment of the present invention relates to a cell comprising a TLR21-receptor and a plasmid encoding an NF- ⁇ B reporter gene, which plasmid is stably maintained in the cell.
- Such cells are very suitable for use in the screening of CpG molecules, more specifically the screening of CpG molecules according to the invention.
- the Examples give ample guidance about how to obtain such a cell comprising a plasmid encoding a reporter gene that can be stably maintained in the cell.
- detection systems based upon secreted alkaline phosphatase were shown to be very suitable for the detection system used.
- the reporter gene is a gene encoding secreted alkaline phosphatase.
- any cell or cell line carrying and expressing a TLR21 that allows introduction and preferably the stable maintenance of a plasmid carrying a NF- ⁇ B reporter gene, preferably the SEAP gene as described above is suitable for testing TLR21-specific CpG ODN's.
- a preferred example of such a suitable cell line for testing TLR21-specific CpG ODN's is the chicken cell line HD11.
- a cell line for use in the detection system is a HD11 cell line comprising a stable plasmid encoding a reporter gene.
- Chicken cell lines such as the HD11 cell line display a whole panel of chicken-TLR's. This may in certain conditions generate a certain background activity.
- non-poultry cell lines such as mammalian cell lines are more preferred cell lines.
- An example of such a mammalian cell line is a HEK293 cell into which the TLR21 has been cloned. Such a cell line is more specifically selective for TLR21-activating signals.
- a cell line for use in the detection system is the mammalian cell line HEK293 comprising a stably maintained reporter gene and into which HEK293 cell the TLR21 has been cloned.
- the disclosure also describes a method for the detection of immunostimulatory oligodeoxynucleotides wherein that method comprises the steps of a) contacting an oligodeoxynucleotide with a cell according to the invention, b) detecting the level of product of the reporter gene.
- the product of the reporter gene is SEAP
- a more preferred form of this method relates to a method for the detection of immunostimulatory oligodeoxynucleotides, wherein the cell is a cell of chicken cell line HD11, or a HEK293 cell line into which chicken TLR21 has been cloned.
- TLR21 is the functional homolog of mammalian TLR9 in avian species (Keestra 2008, Brownlie et al. 2009).
- PCR polymerase chain reaction
- the primers were designed to provide flanking restriction cloning sites (underlined) and a Kozak sequence (italic) to the start and stop codons (bold). RT-PCR was performed using these primers and chicken spleen total RNA as a template. A PCR product of the expected size ( ⁇ 3000 bp) was cloned into pCR2.1-Topo and 5 independent plasmid clones (PI, P2, P12, P13, P14) were sequenced.
- Human embryonic kidney (HEK) cells 293 have been generated in the 1970s by viral transformation (Graham et al., 1977), and are now available to the research community via cell line repositories, such as ATCC.
- pNifty2 is a plasmid that allows the detection of NF ⁇ B transcription factor activation, which is a hallmark of many immunostimulatory actions, toll-like receptor activations amongst them.
- the reporter gene in pNifTy2 dependent in its transcription/translation on NF ⁇ B activation is secreted alkaline phosphatase (SEAP). Details are described in the datasheet of the company selling this plasmid: Invivogen. Transformation/transfection events by pNifty2 are selected in both bacteria and mammalian cells by zeocin addition to the growth media.
- HEK293 cells were transfected with pNifTy2 by standard methods (lipofection), a stable cell line was selected, the functionality of the NF-kB/SEAP axis established by stimulation with human tumour necrosis factor ⁇ (Sigma).
- pcDNA3.1(+)-neo is a standard mammalian expression vector purchased from Invitrogen. Subcloning of the chicken TLR21 gene into this vector was done via flanking Hind III (start codon) and Not I (stop codon) sites that were introduced by PCR. (See figure 1 ).
- This plasmid was then transfected (lipofection) into the clonal HEK293-pNifty2-zeo line, and recombinant cells were selected by addition of both zeocin and G418 into the growth medium. Functionality of the resulting polyclonal recombinant cell line was assessed by stimulation of the culture with ODN-X4 and ODN-HEK1-PTO and detection of SEAP. Superior clonal lines were then identified by the limiting dilution method followed by stimulation and SEAP detection.
- HEK293-pNifTy2-Zeo cells were transfected with pcDNA3.
- 1(+)-Neo-chiTLR21 linearized with Pvu I
- a polyclonal cell line was selected by supplementing the media with 350 ⁇ g/ml zeocin and 600 ⁇ g/ml G418.
- a functionality test was performed by stimulating the cells with ODN-X4 (PDE) and with ODN-HEK1 (PTO).
- SEAP Secreted alkaline phosphatase
- clonal cell line 38 which produced by far the highest SEAP readout signal on response to ODN-X4 (PDE) and ODN-HEK1 (PTO) stimulation, was used.
- Figures 2-5 give an overview of the SEAP activity of the various zeo/G418-double-resistant clonal cell lines.
- Figures 6-8 show the effect of X23 - 4 to X23N - 27 in inducing an amount of the colored product absorbing at 405 nm of the reporter enzyme SEAP in the reporter cells HEK293-pNifty2-chickenTLR21.
- Figure 9 shows the EC 50 value of X23 - 4 to X23N - 27 in picomoles.
- Figure 10 shows the effect of changing the number of the 3'-G's in inducing an amount of the colored product absorbing at 405 nm of the reporter enzyme SEAP in the reporter cells HEK293-pNifty2-chickenTLR21.
Description
- The present invention relates to vaccines comprising immunostimulatory oligodeoxynucleotides and/or vectors comprising these oligodeoxynucleotides.
- During the past two decades, it has emerged in immunological science that the vertebrate immune system possesses mechanisms to detect microbial infection and to trigger rapid immune activation via the receptor-mediated recognition of unique characteristics of pathogens, the so-called pathogen-associated molecular patterns (PAMPs) interacting with cognate host pathogen recognition receptors (PRRs) (Iwasaki A, Medzhitov R. 2001. Science 327, 291-295. Medzhitov R., 2009. ).
- It is now clear that certain forms of pathogen deoxyribonucleic acid (DNA) are amongst these PAMPs. In 1995 it was reported that non-methylated CpG motifs in bacterial DNA trigger murine B-cell activation (Krieg et al. 1995). This study generated for the first time a link between the specific recognition of bacterial immunostimulatory non-methylated CpG-containing DNA and the previously recognized CpG suppression as well as the widespread CpG methylation in mammalian DNA. The most effective B cell stimulatory non-methylated CpG oligodeoxynucleotide (CpG ODN) was shown to possess the sequence element GACGTT.
- The next landmark paper in the field was published by Shizuo Akira's laboratory in Osaka/Japan (Hemmi et al. 2000). By a gene cloning and a targeted gene knockout approach in mice it could be unequivocally shown, that the cellular response in mice to CpG-ODNs is mediated by the toll-like receptor 9 (TLR9). Subsequently it was shown that the CpG-ODNs are agonists for TLR9 signaling predominantly via the NF kappa-B pathway (Medzhitov 2001). In the following decade, quite a number of studies have been published on basic research topics and on general potential immunotherapeutic applications (e. g. reviewed in Krieg 2002, 2003, 2006; Klinman 2004, Vollmer 2005, Wilson et al. 2006, Kindrachuk et al. 2008, Dorn and Kippenberger 2008, Vollmer and Krieg 2009, Wilson et al. 2009). A number of review articles focus on anti-infective applications of CpG-ODNs (Krieg 2007), the use of TLR9 agonists in the treatment of cancer (Krieg 2007, Weiner 2009), TLR9 activation for asthma and allergy treatment (Kline 2007, Kline and Krieg 2008, Fonseca and Kline 2009) and as vaccine adjuvants (Klinman et al. 2004, Klinman 2006, Daubenberger 2007, Wagner 2009, Mutwiri et al. 2009, Klinman et al. 2009).
-
WO2004/005476 discloses various CpG motifs for therapeutic use in mammals. -
WO2012/089800 discloses CpG motifs and their application in TLR interaction. - CpG ODNs have also been described and discussed as immunostimulatory agents and vaccine adjuvants in veterinary applications, particularly in bovines, pigs, sheep, dogs, chicken and fish (Babiuk et al. 2003, Carrington and Secombes 2006, Griebel et al. 2005, Mutwiri et al. 2003, Singh and O'Hagan 2003, Werling and Jungi 2003).
- In the field of veterinary uses in chickens, the use of CpG oligodeoxynucleotides in e.g. vaccines to protect chickens against Newcastle Disease has been described (Linghua 2007).
- It has recently been shown that in chicken, TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides (Brownlie et al., 2009).
- The design of specific CpG ODN's as immunomodulators has so far been quite random. This is especially true for non-mammalian CpG ODN's. The reason for this is multi-factorial; first of all there is no knowledge about correlation between immuno modulatory CpG motifs for human TLR's and for TLR's in non-human, let alone non-mammalian species. Secondly, there are no cell-systems available with a sufficiently low background to noise level to selectively test the effects of very low concentrations of CpG ODN's. Moreover, there are no high-throughput screening methods available and even if there were, there is no clear correlation between in vivo versus in vitro efficacy of CpG ODN's as immuno-modulators in non-mammalian species. Thus, there clearly is a need for novel CpG ODN's that have a high immuno-modulatory effect and therefore are effective in low doses. And there is a need for selective and sensitive CpG ODN selection systems for veterinary purposes that show a correlation between in vitro and in vivo activity of CpG-activity.
- It is one of the objectives of the present invention to provide vaccines comprising such novel CpG ODN's.
- In this respect the present invention relates to a vaccine for preventing or combating an infectious disease in poultry, comprising an immunostimulatory amount of an immunostimulatory non-methylated oligodeoxynucleotide having the general formula
5' [G]x {T C G T C G}n T C G [G]z 3'
wherein x = 3-20; z = 0-10; n = 2-100; or a pharmaceutically acceptable salt thereof, and/or a vector comprising the oligodeoxynucleotide, an immunogenic amount of an antigen component or genetic information encoding an antigen component, wherein said antigen component is, or is derived from a virus or micro-organism that in its wild-type form is pathogenic to poultry, and a pharmaceutically acceptable carrier. - An "immunostimulatory non-methylated oligodeoxynucleotide" refers to an oligodeoxynucleotide, which contains a non-methylated cytidine-phosphate-guanosine di-nucleotide sequence that stimulates the initiation of signaling cascades leading to activation of transcription factors such as NF-κB or Interferon Regulatory Factor 3 (IRF3). It is this activation that in turn results in the expression of inflammatory cytokines and other cellular activation events. NF-κB binding sites and gene expression influenced by NF-κB are i.a. described by Schindler and Baichwal (1994).
- The term oligodeoxynucleotide means a short nucleic acid polymer of deoxynucleotides; i.e. a molecule comprising a multitude of deoxyriboses, linked to a phosphate group and to an exchangeable organic base. Such an organic base is a substituted pyrimidine or a substituted purine. Examples are cytosine and thymine respectively adenine and guanine.
- The oligonucleotides according to the invention may comprise modifications. Examples of such modifications are e.g. modifications in the phosphodiester internucleoside bridge located at the 3' and/or 5' end of a nucleoside. Such modifications relate i.a. to the replacement of a phosphodiester by e.g. a phosphorothioate or a phosphorodithioate.
- Other modifications are e.g. replacements of a phosphodiester bridge by a dephospho bridge. Examples of dephospho bridges are methylhydroxylamine, formacetal and dimethylenesulfone groups.
- Still other modifications are modifications that concern the replacement of a natural nucleoside base by a non-natural nucleoside base such as inosine, 5-fluorocytosine, 7-deaza-7-substituted guanine, 7-deaza-8-substituted guanine , 2-thiouracil, dihydrouracil, 5-bromo-cytosine, 6-substituted cytosines, N4-substituted cytosines,
- Again other modifications are modifications concerning the replacement of a sugar unit; a β-ribose sugar or a β-D-2'-ribose sugar unit by a modified sugar unit such as e.g. an L-2'-deoxyribose or 2'-L-arabinose.
- A text book giving further insight in oligonucleotides is e.g. "PCR Primer: A Laboratory Manual", Second Edition, 2003, Edited By Carl W. Dieffenbach, National Institute of Allergy and Infectious Diseases ; Gabriela S. Dreksler, Uniformed Services University of the Health Sciences, Cold Spring Harbor Laboratory Press ISBN 978-087969654-2.
- The structure 5' { T C G T C G}n 3' carrying the CpG motif represents the active immunostimulating moiety of an ODN according to the invention. Therefore, the present invention provides immunostimulatory oligodeoxynucleotides that comprise this so-called "backbone".
- It was found that the backbone of an oligodeoxynucleotide according to the invention, the structure 5' { T C G T C G}n 3' must be present at least two, preferably three times. Therefore, n should be at least two. It was also found that the activity of the oligodeoxynucleotides increases when n increases. This effect is leveling when n increases. Basically, the number n of the backbone structure should therefore be at least 2. Preferably, the range of n is 3 ≤ n ≤ 100, merely because of the fact that the longer the synthetic sequence the more difficult it is to make. In practice preferably the range of n is 3 ≤ n ≤ 18. More preferably, the range of n is 4 ≤ n ≤ 18, even more preferably the range of n is 5 ≤ n ≤ 18, still even more preferably the range of n is 6 ≤ n ≤ 18.
- The identification of CpG ODN's for use in the invention was made possible i.a. by using a more selective detection system than the systems currently in use for the detection of NF-κB activation. Brownlie at al. (2009) describe an NF-κB luciferase based reporter system. Other systems are e.g. based upon IL-8 transcript measurement or cytokine secretion or the detection of NO secretion.
- Contrary to this, in the present invention a secreted alkaline phosphatase based detection system (SEAP) was used. SEAP is a reporter enzyme in mammalian systems (Yang et al., 1997). This system turned out to be surprisingly sensitive and in addition surprisingly provides a close correlation between the in vitro and in vivo activities of the CpG ODN's tested. The SEAP system was used with para-nitrophenylphosphate (pNPP) as a substrate.
- Another improvement over existing systems was the introduction and stable maintenance in cells of the plasmid carrying the SEAP gene. Up till now, all detection systems used transient transfection of cells with the reporter gene. It is due to the introduction and stable maintenance in cells of the reporter gene that now for the first time a dose/response curve could be made. Such a curve is essential if a reliable comparison between various CpG ODN's activity is to be made.
- Therefore, the methods and cell lines described in detail in the Examples section of the present invention allow for the first time to make a reliable side-by-side comparison between various CpG ODN's.
- Further details of the system used are given in the Examples section.
- It was found that an increase in the number of G's at the 5'-end of the structure 5' [G]x { T C G T C G}n T C G [G]z 3' leads to an increase of the activity of the CpG ODN. The value x should preferably be at least 3, but increasing numbers of G's up to 20 G's improve the activity of the CpG ODN. Therefore more preferably, x is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 in that increasing order of preference.
- It was also found that an increase in the number of G's ate the 3'-end of the structure 5' [G]x { T C G T C G}n T C G [G]z 3' leads to a (slight) decrease of the activity of the CpG ODN. The value z should preferably be 10 or less than 10, but decreasing numbers of G's down to 0 G's improves the activity of the CpG ODN. Therefore more preferably z is 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0, in that increasing order of preference.
- As said above, several kinds of modifications in the phosphodiester internucleoside bridge located at the 3' and/or 5' end of a nucleoside are feasible. But basically, depending upon the way of synthesis, usual common types of bonds between two nucleotides are: phosphodiester (PDE) bonds and phosphorothioate (PTO) bonds. In order to improve the stability and the immunostimulatory effect of CpG ODN's, the building blocks of synthetic oligodeoxynucleotides are usually provided with phosphorothioates, so that they form PTO bonds.
- It was surprisingly found, however, that when only the 5' [G]x and the 3' [G]z nucleotides are bound by PTO bonds and the other nucleotides are bound by PDE bonds, the efficacy of the oligodeoxynucleotide according to the invention is further increased. (In such cases, the 5' [G]x to { T C G T C G}n T C G [G]z 3' bond is a PTO, while the 5' [G]z { T C G T C G}n T C G to [G]z 3' bond is a PDE.)
- Therefore, the disclosure also describes oligodeoxynucleotides wherein the 5' [G]z and the 3' [G]z nucleotides have a phosphorothioate binding and the other nucleotides have a phosphodiester binding.
- Normally, CpG oligodeoxynucleotides are active in nanomolar amounts, both in the in vitro test system and in vivo.
- Surprisingly, however, the CpG oligodeoxynucleotides according to the invention are even active in picomolar (sub-nanomolar) amounts; their EC50 is below 1 nM.
- The half-maximal effective concentration (EC50) of an oligodeoxynucleotide is the amount of oligodeoxynucleotide that is necessary to induce an amount of the reporter enzyme SEAP (that produces the colored product absorbing at 405 nm) in the reporter cells (HEK293-pNifty2-chickenTLR21 or HD11-pNifTy2Hyg) that gives a half-maximal enzymatic reaction rate. If the EC50 of an oligodeoxynucleotide is below 1 nM in these cells, it is considered to be active in picomolar (sub-nanomolar) amounts.
- It is very well possible to link an oligodeoxynucleotide according to the invention to a carrier or hapten, via a reactive chemical group. Such linkage enhances the immunostimulatory effect of the combined molecules.
- Mere examples of such components are e.g. digoxigenin, aminohexyl-, Texas red and biotin.
- Preferred carriers or haptens are 3'- and 5'-labeled Texas red and 5'-labeled digoxigenin. The linkage of oligodeoxynucleotides to haptens/carriers is well-known in the art.
- Another embodiment of the invention relates to a vaccine comprising a vector comprising an immunostimulatory non-methylated oligodeoxynucleotide as described. Such a vector can be a nucleic acid molecule such as a plasmid, a virus, a bacteriophage or any other vector used in molecular biology. Merely as an example: a vector comprising an immunostimulatory non-methylated oligodeoxynucleotide can e.g. be a DNA molecule such as a plasmid that can be multiplied in bacteria, into which an immunostimulatory non-methylated oligodeoxynucleotide according to the invention has been cloned. Such a plasmid preferably has an active origin of replication, causing high numbers of the plasmid to be present in the host. Growing such bacteria on a large scale followed by isolation of the plasmids provides an alternative for the synthetic production of the immunostimulatory non-methylated oligodeoxynucleotide according to the invention.
- One of the aims of the present invention is to provide new CpG ODN's that can be used as successful immunostimulating components in vaccines that prevent or combat infectious disease together with an antigen component or genetic information encoding an antigen component, and a pharmaceutically acceptable carrier.
- In general, the term antigen component refers to a composition of matter that comprises at least one epitope that can induce, stimulate or enhance an immune response when administered to a human or an animal.
- The antigen component may be any kind of antigen component but preferably is derived from a micro-organism or virus that in its wild-type form is pathogenic to humans or animals.
- The antigen component can be the whole pathogen, preferably in an inactivated or attenuated form, an extract of the pathogen or an immunogenic protein of the pathogen.
- If the antigen component is an immunogenic protein of the pathogen, that immunogenic protein is preferably expressed in and recovered from in vitro cultured cells.
- Therefore, the invetion relates to a vaccine for preventing or combating infectious disease characterised in that said vaccine comprises an immunostimulating amount of an oligodeoxynucleotide according to the invention and/or a vector according to the invention, an immunogenic amount of an antigen component or genetic information encoding an antigen component, and a pharmaceutically acceptable carrier.
- Of course, the immunostimulating amount of the oligodeoxynucleotide and the immunogenic amount of the antigen component are strongly interrelated. It is one of the merits of the present invention that the presence of the oligodeoxynucleotide according to the invention can lower the amount of antigen component that is necessary to prevent or combat infectious disease.
- The amount of antigen component that is necessary to prevent or combat infectious disease is referred to as the immunogenic amount of the antigen component.
- An immunostimulating amount of the oligodeoxynucleotide is the amount that is capable of decreasing the immunogenic amount of the antigen component, i.e. the amount of the antigen component that is necessary to prevent or combat an infectious disease.
- So basically, the wording "immunostimulating amount of the oligodeoxynucleotide" and "immunogenic amount" must be seen in relation to each other.
- It goes without saying that, if the vaccine comprises genetic information encoding an antigen component, the amount of antigen component expressed by this genetic information should be enough to prevent or combat infectious disease, i.e.; it must be an immunogenic amount.
- The fact that the non-methylated oligodeoxynucleotides according to the invention are immunostimulatory, means that they enhance the immunological efficacy of antigen components in vaccines. For that reason, vaccines according to the invention will in many cases comprise less of the antigen component or the genetic information encoding the antigen component than would be the case if no oligodeoxynucleotides according to the invention would be present.
- In some cases an antigen component as such, without the addition of immunostimulatory oligonucleotides, may have such low immunogenic properties that high amounts must be given anyway, albeit without reaching the desired immunogenic level. In such cases, the antigen component can be given in the usual high concentration, however now together with an oligodeoxynucleotide according to the invention in order to so obtain the desired level of immunogenicity.
- Thus, the amount of the antigen component or the genetic information encoding the antigen component to be administered with a oligonucleotide according to the invention would as a rule of thumb be equal or below the amount given in the absence of the oligonucleotide. The skilled person involved in the manufacturing of a specific vaccines, would know that amount for that specific vaccine. Also, the Examples give e.g. ample guidance for the amount of antigen components to be used, e.g. in three different inactivated viral vaccines: Newcastle disease virus vaccine, Infectious Bronchitis virus vaccine and Turkey Rhinotracheitis vaccine.
- The amount of the oligodeoxynucleotide according to the invention that needs to be administered together with the antigen component or the genetic information encoding the antigen component depends both on the selected oligodeoxynucleotide and the antigen component.
- A very suitable amount of oligodeoxynucleotide according to the invention would usually vary between 1 and 100 nanomol. Very good in vivo results have e.g. been obtained with 1-10 µg of oligodeoxynucleotides according to the invention with an average length of 30 deoxynucleotides that were shown to be active in in vitro tests in the nanomolar range.
- If an oligodeoxynucleotide is chosen from the group of oligodeoxynucleotides that are active in the picomolar range, the skilled person would realise that amounts below, possibly far below, 1 nanomol, i.e. picomolar amounts, would be worth testing before testing nanomolar amounts.
- Vaccines according to the invention comprise a pharmaceutically acceptable carrier. The nature of this carrier depends i.a. upon the route of administration. If the administration route is through the oral or intranasal route, the carrier could be as simple as sterile water, a physiological salt solution or a buffer. If injection is the preferred route, the carrier should preferably be isotonic and have pH restrictions that make it suitable for injection. Such carriers however are extensively known in the art.
- Vaccines according to the invention may, in addition to the antigen component or the genetic information encoding the antigen component, and an oligodeoxynucleotide according to the invention, comprise an adjuvant. Adjuvants in general are substances that boost the immune response of the host in a non-specific manner.
- Many adjuvants are known in the art to be suitable, such as Freund's Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers and poly-anions such as dextran sulphate, carbopol and pyran, alum hydroxide. Also frequently used are alum phosphate, saponins, vegetable oils such as tocopherol and mineral oils. Very efficient adjuvants are oil-in-water emulsions and especially water-in-oil emulsions, further also referred to as are oil-in-water adjuvants and water-in-oil adjuvants. Such emulsions are well-known in the art. Thus, preferably, the vaccine comprises a water-in-oil adjuvant.
- Preferably the antigen component is, or is derived from a virus or micro-organism that in its wild-type form is pathogenic to poultry.
- More preferably, said virus or micro-organism is selected from the group consisting of Infectious Bronchitis virus, Newcastle Disease virus, Infectious Bursal Disease (Gumboro), Chicken Anaemia agent, Avian Reovirus, Mycoplasma gallisepticum, Turkey Rhinotracheitis virus, Haemophilus paragallinarum (Coryza), Chicken Poxvirus, Avian Encephalomyelitis virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, Eimeria species, Ornithobacterium rhinotracheale, Pasteurella multocida, Mycoplasma synoviae, Salmonella species and Escherichia coli.
- The disclosure also describes an immunostimulatory non-methylated oligodeoxynucleotide for use as a medicament.
- The present invention relates to vaccines comprising an immunostimulatory non-methylated oligodeoxynucleotide according for use in preventing or combating infectious disease in poultry
- Up till now, all detection systems used transient transfection of cells with the reporter gene. Such transient systems do not allow for a reliable side-by-side comparison of the efficacy of CpG ODN's. As said above, a major improvement over existing systems was the introduction and stable maintenance in cells, of the plasmid carrying the reporter gene. Stable means that the plasmid remains present in the cell after several cell division cycles.
- Frequently, stable maintenance of a plasmid is obtained by growing the cells under the pressure of one or more selective agents, such as antibiotics for which a resistance gene is present on the plasmid. Loss of the plasmid would then cause the cell that lost the plasmid to die. Remaining viable cells would still harbour the plasmid.
- Another way of stable maintenance would be transfection with linearized plasmids. Such plasmids usually become integrated in the genome of the cell, and thus be stably maintained. Thus, still another embodiment of the present invention relates to a cell comprising a TLR21-receptor and a plasmid encoding an NF-κB reporter gene, which plasmid is stably maintained in the cell. Such cells are very suitable for use in the screening of CpG molecules, more specifically the screening of CpG molecules according to the invention.
- The Examples give ample guidance about how to obtain such a cell comprising a plasmid encoding a reporter gene that can be stably maintained in the cell.
- As also mentioned above, detection systems based upon secreted alkaline phosphatase (SEAP) were shown to be very suitable for the detection system used.
- Thus, preferably the reporter gene is a gene encoding secreted alkaline phosphatase.
- Basically, any cell or cell line carrying and expressing a TLR21 that allows introduction and preferably the stable maintenance of a plasmid carrying a NF-κB reporter gene, preferably the SEAP gene as described above is suitable for testing TLR21-specific CpG ODN's.
- A preferred example of such a suitable cell line for testing TLR21-specific CpG ODN's is the chicken cell line HD11.
- Therefore, preferably, a cell line for use in the detection system is a HD11 cell line comprising a stable plasmid encoding a reporter gene.
- Chicken cell lines such as the HD11 cell line display a whole panel of chicken-TLR's. This may in certain conditions generate a certain background activity.
- Therefore, non-poultry cell lines such as mammalian cell lines are more preferred cell lines. An example of such a mammalian cell line is a HEK293 cell into which the TLR21 has been cloned. Such a cell line is more specifically selective for TLR21-activating signals.
- Therefore, more preferably, a cell line for use in the detection system is the mammalian cell line HEK293 comprising a stably maintained reporter gene and into which HEK293 cell the TLR21 has been cloned.
- The disclosure also describes a method for the detection of immunostimulatory oligodeoxynucleotides wherein that method comprises the steps of a) contacting an oligodeoxynucleotide with a cell according to the invention, b) detecting the level of product of the reporter gene.
- In a preferred form of this method, the product of the reporter gene is SEAP
- A more preferred form of this method relates to a method for the detection of immunostimulatory oligodeoxynucleotides, wherein the cell is a cell of chicken cell line HD11, or a HEK293 cell line into which chicken TLR21 has been cloned.
- Recent progress in chicken TLR research suggests that TLR21 is the functional homolog of mammalian TLR9 in avian species (Keestra 2008, Brownlie et al. 2009).
- Based on the Genbank database sequence NM_001030558, a primer pair was synthesized for the polymerase chain reaction (PCR) amplification of the chicken TLR21 gene:
- Ga-TLR21-for1
GAAGCTT ACC ATGATGGAGACAGCGGAGAAGGC - Ga-TLR21-rev1
GGCGGCCG CTACATCTGTTTGTCTCCTTCCCTG - The primers were designed to provide flanking restriction cloning sites (underlined) and a Kozak sequence (italic) to the start and stop codons (bold). RT-PCR was performed using these primers and chicken spleen total RNA as a template. A PCR product of the expected size (∼ 3000 bp) was cloned into pCR2.1-Topo and 5 independent plasmid clones (PI, P2, P12, P13, P14) were sequenced.
-
- Human embryonic kidney (HEK) cells 293 have been generated in the 1970s by viral transformation (Graham et al., 1977), and are now available to the research community via cell line repositories, such as ATCC.
- pNifty2 is a plasmid that allows the detection of NFκB transcription factor activation, which is a hallmark of many immunostimulatory actions, toll-like receptor activations amongst them. The reporter gene in pNifTy2 dependent in its transcription/translation on NFκB activation is secreted alkaline phosphatase (SEAP). Details are described in the datasheet of the company selling this plasmid: Invivogen. Transformation/transfection events by pNifty2 are selected in both bacteria and mammalian cells by zeocin addition to the growth media.
- HEK293 cells were transfected with pNifTy2 by standard methods (lipofection), a stable cell line was selected, the functionality of the NF-kB/SEAP axis established by stimulation with human tumour necrosis factor α (Sigma). Secreted SEAP in the culture supernatant of stimulated cells was determined by a microtiter plate colorimetric assay employing the chromogenic substrate p-nitrophenylphosphate (pNPP, 5 mM) in an alkaline buffer (50 mM NaHCO3, pH9.6, 2 mM MgCl2). Colour development (λ = 405 nm) was monitored by a microtiter plate reader. This readout was also used for selecting clonal lines (by the limiting dilution method) with high signal to noise ratios. One of these selected clones (dubbed clone 11) was then used for further studies with chicken TLR21.
- pcDNA3.1(+)-neo is a standard mammalian expression vector purchased from Invitrogen. Subcloning of the chicken TLR21 gene into this vector was done via flanking Hind III (start codon) and Not I (stop codon) sites that were introduced by PCR. (See
figure 1 ). - This plasmid was then transfected (lipofection) into the clonal HEK293-pNifty2-zeo line, and recombinant cells were selected by addition of both zeocin and G418 into the growth medium. Functionality of the resulting polyclonal recombinant cell line was assessed by stimulation of the culture with ODN-X4 and ODN-HEK1-PTO and detection of SEAP. Superior clonal lines were then identified by the limiting dilution method followed by stimulation and SEAP detection.
- SEAP is a reporter enzyme in mammalian systems (Yang et al., 1997). SEAP is a secreted form of human embryonic alkaline phosphatase. Its main advantages are the high stability and the extremely high specific activity, which ensure sensitivity and robustness of detection. Several substrates have been described for SEAP detection, but the economical and robust pNPP was selected, as its reaction product p-nitrophenolate is detected with high sensitivity (ε405 = 18500 M-1 cm-1). In our test setups, we perform kinetic assays, because they provide a wider dynamic range of quantification.
- HEK293-pNifTy2-Zeo cells were transfected with pcDNA3. 1(+)-Neo-chiTLR21 (linearized with Pvu I) and a polyclonal cell line was selected by supplementing the media with 350 µg/ml zeocin and 600 µg/ml G418. A functionality test was performed by stimulating the cells with ODN-X4 (PDE) and with ODN-HEK1 (PTO). Secreted alkaline phosphatase (SEAP) was produced by the selected cells, but not by the parental HEK293-pNifTy2-Zeo cell line. Single cell cloning was performed and individual clones were analyzed for their responsiveness to ODN-X4 (PDE) (GGGGGGTTCGTTTTCGTTTTCGTTGGGGG) and ODN-HEK1 (PTO) (TCGTCGTTTTGTCGTTTGTCGTT).
- Out of 46 zeo/G418-double-resistant clonal cell lines, only 3 were clearly responsive to the ODN stimuli, while 3 - 4 further cell lines showed weaker signals. 85% of the selected clones were, therefore, not functional.
- For all further studies,
clonal cell line 38, which produced by far the highest SEAP readout signal on response to ODN-X4 (PDE) and ODN-HEK1 (PTO) stimulation, was used.
Figures 2-5 give an overview of the SEAP activity of the various zeo/G418-double-resistant clonal cell lines. - In this homopolymer series based on the motif 5' [G]x { T C G T C G}n T C G [G]z 3'
the 3'-dG run was shortened to one G for all ODNs tested.
E.g. : example X23N - 5 represents [G]x { T C G T C G}n T C G [G]z 3'
wherein x=7, z=0 and n=2: G7 {T C G T C G }2 T C G
E.g. : example X23N - 7 represents [G]x { T C G T C G}n T C G [G]z 3'
wherein x=7, z=0 and n=3: G7 { T C G T C G }3 T C G
X23N-5 GGGGGGGTCGTCGTCGTCGTCG
X23N-7 GGGGGGGTCGTCGTCGTCGTCGTCGTCG
X23N-9 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-11 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-13 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-15 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-17 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-19 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-21 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-23 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-25 GGGGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG
X23N-27 -
Figures 6-8 show the effect of X23 - 4 to X23N - 27 in inducing an amount of the colored product absorbing at 405 nm of the reporter enzyme SEAP in the reporter cells HEK293-pNifty2-chickenTLR21. - Surprisingly, it can be concluded from
figure 6 , that already if n = 3, the immuno-stimulatory effect is unexpectedly high. This effect is clearly quantified in an unexpectedly low EC50 value infigure 9 (vide infra). - Furthermore, it can be concluded from
figures 6-8 , that an increase from n=3 to n=13 gives an even further increase in activity (= a decrease in EC50). This increase shows a rather fast leveling off, once n reaches the value of 5. -
Figure 9 shows the EC50 value of X23 - 4 to X23N - 27 in picomoles. - As can be seen from
figure 9 , already at a value of n = 4, the EC50 is only slightly above 200 pM, whereas from a value of n = 10 onwards the EC50 value reaches a plateau of slightly under 100 pM. - In this homopolymer series based on the motif 5' [G]x { T C G T C G}nT C G [G]z 3'
the number of 3'-G's was modified while n = 4. - The following constructs were tested:
- X23-six 5'-GGGGGGTCGTCGTCGTCGTCGTCGGGGG-3'
(=X23, standard 1) - X4-pent 5'-GGGGGGTTCGTTTTCGTTTTCGTTTTCGTTTTCGTTGGGGG-3'
(= standard 2) - X23-nine-3455 5'-GGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCGGGGG-3'
(→ n=4, x=5, z=4) - X23-nine-3451 5'-GGGGGTCGTCGTCGTCGTCGTCGTCGTCGTCG-3'
(→ n=4, x=5, z=0) -
Figure 10 shows the effect of changing the number of the 3'-G's in inducing an amount of the colored product absorbing at 405 nm of the reporter enzyme SEAP in the reporter cells HEK293-pNifty2-chickenTLR21. - The EC50 for these CpG motifs is as follows:
X4-pent (standard control) 340 pM X23-nine-3455 (n=4, x=5, z=4) << 100 pM X23-nine-3451 (n=4, x=5, z=0) << 100 pM - From this it can be derived that the number of 3'-G's is not particularly relevant provided that z=4 or less than 4, with regard to the EC50.
- Legend to the figures:
-
Figure 1 : Plasmid map of pcDNA3.1(+)-chiTLR21 -
Figure 2-5 : overview of the SEAP activity of the various zeo/G418-double-resistant clonal cell lines. -
Figure 6-8 : these figures show the effect of X23 - 4 to X23N - 27 in inducing an amount of the colored product absorbing at 405 nm of the reporter enzyme SEAP in the reporter cells (HEK293-pNifty2-chickenTLR21) -
Figure 9 : this figure shows the EC50 value of X23 - 4 to X23N - 27 in picomoles. -
Figure 10 : this figure shows the EC50 values of X4-pent (standard control), X23-six, X23- nine-3455 and X23-nine-3451. -
- Babiuk L.A., Gomis S., Hecker R., 2003. Molecular approaches to disease control. Poult. Sci. 82, 870-875.
- Brownlie, R., Zhu J., Allan B., Mutwiri G.K., Babiuk L.A., Potter A., Griebel P., 2009. Chicken TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides. Mol. Immunol. 46, 3163-3170
- Carrington A.C., Secombes C.J., 2006. A review of CpGs and their relevance to aquaculture. Vet. Immunol. Immunopathol. 112, 87-101.
- Daubenberger C.A., 2007. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr. Opin. Mol. Ther. 9, 45-52.
- Dorn A., Kippenberger S., 2008. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr. Opin. Mol. Ther. 10, 10-20.
- Fonseca D.E., Kline J.N., 2009.Use of CpG oligodeoxynucleotides in treatment of asthma and allergic disease. Adv. Drug Deliv. Rev. 61, 256-262.
- Graham, F.L., Smiley, J., Russell, W.C., Nairn, R., 1977. Characteristics of a human cell line transformed by DNA from .
- Griebel P.J., Brownlie R., Manuja A., Nichani A., Mookherjee N., Popowych Y., Mutwiri G., Hecker R., Babiuk L.A., 2005. Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression. Vet. Immunol. Immunopathol. 108, 11-16.
- Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
- Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. 2010. Science 327, 291-295.
- Keestra A.M., 2008. Molecular dissection of the chicken Toll-like receptor repertoire. PhD thesis (Proefschrift), University of Utrecht, The Netherlands
- Kline J.N., 2007. Immunotherapy of asthma using CpG oligodeoxynucleotides. Immunol. Res. 39, 279-286.
- Kline J.N., Krieg A.M., 2008. Toll-.
- Klinman D.M., 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249-258.
- Klinman D.M, Currie D., Gursel I., Verthelyi D., 2004. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201-216.
- Klinman D.M., 2006. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25, 135-154.
- Klinman D.M., Klaschik S., Sato T., Tross D., 2009. CpG oligodeoxynucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug Deliv. Rev. 61, 248-255.
- Kindrachuk J., Potter J., Wilson H.L., Griebel P., Babiuk L.A., Napper S., 2008. Activation and regulation of toll-like receptor 9: CpGs and beyond. Mini Rev. Med. Chem. 8, 590-600.
- Krieg A.M., Yi A,K., Matson S,, Waldschmidt T,J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M., 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
- Krieg A.M., 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20,709-760.
- Krieg A.M., 2003. CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9, 831-835.
- Krieg A.M., 2006. Therapeutic potential of Toll-.
- Krieg A.M., 2007a. Anti-infective applications of toll-.
- Krieg A.M., 2007b. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117, 1184-1194.
- Linghua Zhang et al., 2007. Vaccination with Newcatle disease vaccine and CpG oligodeoxynucleotides induces specific immunity and protection against Newcastle disease virus in SPF chicken. Vet. Immun. And Immunopath. 115, 216-222.
- Medzhitov R., 2001. CpG DNA: security code for host defense. Nat. Immunol. 2, 15-16.
- Medzhitov R., Approaching the asymptote: 20 years later. 2009. )
- Mutwiri G., van Drunen Littel-van den Hurk S., Babiuk L.A., 2009. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv. Drug Deliv. Rev. 61, 226-232.
- Mutwiri G., Pontarollo R., Babiuk S., Griebel P., van Drunen Littel-van den Hurk S., Mena A., Tsang C., Alcon V., Nichani A., Ioannou X., Gomis S., Townsend H., Hecker R., Potter A., Babiuk L.A., 2003. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet. Immunol. Immunopathol. 91, 89-103.
- Schindler, U., and Baichwal, V.R., 1994. Moll. Cell. Biol. 14: 5820-5831.
- Singh M., O'Hagan D.T., 2003. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol. 33, 469-478.
- Vollmer J., 2005. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin. Biol. Ther. 5, 673-682.
- Vollmer J., Krieg A.M., 2009. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61, 195-204.
- Wagner H., 2009. The immunogenicity of CpG-antigen conjugates. Adv. Drug. Deliv. Rev. 61, 243-247.
- Weiner G.J., 2009. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies. Adv. Drug Deliv. Rev. 61, 263-267.
- Werling D., Jungi T.W., 2003. TOLL-like receptors linking innate and adaptive immune response. Vet. Immunol. Immunopathol. 91, 1-12.
- Wilson H.L., Dar A., Napper S.K., Marianela Lopez A., Babiuk L.A., Mutwiri G.K., 2006. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25, 183-213.
- Wilson K.D., de Jong S.D., Tam Y.K., 2009. Lipid-based delivery of CpG oligodeoxynucleotides enhances immunotherapeutic efficacy. Adv. Drug Deliv. Rev. 61, 233-242.
- Yang, T.T., Sinai, P., Kitts, P.A., Kain, S.R., 1997. Quantification of gene expression with a secreted alkaline phosphatase reporter system. .
-
- <110> Intervet International BV
- <120> Immunostimulatory oligodeoxynucleotides
- <130> 2011.014
- <160> 19
- <170> PatentIn version 3.5
- <210> 1
<211> 33
<212> DNA
<213> synthetic DNA - <400> 1
gaagcttacc atgatggaga cagcggagaa ggc 33 - <210> 2
<211> 33
<212> DNA
<213> synthetic DNA - <400> 2
ggcggccgct acatctgttt gtctccttcc ctg 33 - <210> 3
<211> 2935
<212> DNA
<213> synthetic DNA - <400> 3
- <210> 4
<211> 22
<212> DNA
<213> synthetic DNA - <400> 4
gggggggtcg tcgtcgtcgtcg 22 - <210> 5
<211> 28
<212> DNA
<213> synthetic DNA - <400> 5
gggggggtcg tcgtcgtcgt cgtcgtcg 28 - <210> 6
<211> 34
<212> DNA
<213> synthetic DNA - <400> 6
gggggggtcg tcgtcgtcgt cgtcgtcgtc gtcg 34 - <210> 7
<211> 40
<212> DNA
<213> synthetic DNA - <400> 7
gggggggtcg tcgtcgtcgt cgtcgtcgtc gtcgtcgtcg 40 - <210> 8
<211> 46
<212> DNA
<213> synthetic DNA - <400> 8
gggggggtcg tcgtcgtcgt cgtcgtcgtc gtcgtcgtcg tcgtcg 46 - <210> 9
<211> 52
<212> DNA
<213> synthetic DNA - <400> 9
gggggggtcg tcgtcgtcgt cgtcgtcgtc gtcgtcgtcg tcgtcgtcgt cg 52 - <210> 10
<211> 58
<212> DNA
<213> synthetic DNA - <400> 10
gggggggtcg tcgtcgtcgt cgtcgtcgtc gtcgtcgtcg tcgtcgtcgt cgtcgtcg 58 - <210> 11
<211> 64
<212> DNA
<213> synthetic DNA - <400> 11
- <210> 12
<211> 70
<212> DNA
<213> synthetic DNA - <400> 12
- <210> 13
<211> 76
<212> DNA
<213> synthetic DNA - <400> 13
- <210> 14
<211> 82
<212> DNA
<213> synthetic DNA - <400> 14
- <210> 15
<211> 88
<212> DNA
<213> synthetic DNA - <400> 15
- <210> 16
<211> 28
<212> DNA
<213> synthetic DNA - <400> 16
ggggggtcgt cgtcgtcgtc gtcggggg 28 - <210> 17
<211> 41
<212> DNA
<213> synthetic DNA - <400> 17
ggggggttcg ttttcgtttt cgttttcgtt ttcgttggggg 41 - <210> 18
<211> 36
<212> DNA
<213> synthetic DNA - <400> 18
gggggtcgtc gtcgtcgtcg tcgtcgtcgt cggggg 36 - <210> 19
<211> 32
<212> DNA
<213> synthetic DNA - <400> 19
gggggtcgtc gtcgtcgtcg tcgtcgtcgtcg 32
Claims (5)
- Vaccine for preventing or combating an infectious disease in poultry, characterised in that said vaccine comprises (a) an immunostimulatory amount of an immunostimulatory non-methylated oligodeoxynucleotide having the general formula
5' [G]x { T C G T C G}n T C G [G]z 3'
whereinx = 3-20;z = 0-10;n = 2-100;or a pharmaceutically acceptable salt thereof, and/or a vector comprising the oligodeoxynucleotide, (b) an immunogenic amount of an antigen component or genetic information encoding an antigen component, wherein said antigen component is, or is derived from a virus or micro-organism that in its wild-type form is pathogenic to poultry, and (c) a pharmaceutically acceptable carrier. - A vaccine according to claim 1, characterised in that
x = 3-10;
z < 5;
n = 3-18; - A vaccine according to claim 1 or 2, wherein the 5' [G]x and the 3' [G]z nucleotides have a phosphorothioate binding and the other nucleotides have a phosphodiester binding.
- A vaccine according to any of claims 1-3, wherein said oligodeoxynucleotide is coupled to a carrier or hapten.
- Vaccine according to any of the preceding claims, characterised in that said virus or micro-organism is selected from the group consisting of Infectious Bronchitis virus, Newcastle Disease virus, Infectious Bursal Disease (Gumboro), Chicken Anaemia agent, Avian Reovirus, Mycoplasma gallisepticum, Turkey Rhinotracheitis virus, Haemophilus paragallinarum (Coryza), Chicken Poxvirus, Avian Encephalomyelitis virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, Eimeria species, Ornithobacterium rhinotracheale, Pasteurella multocida, Mycoplasma synoviae, Salmonella species and E. coli.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL12726042T PL2714908T3 (en) | 2011-05-26 | 2012-05-25 | Immunostimulatory oligodeoxynucleotides |
EP12726042.0A EP2714908B1 (en) | 2011-05-26 | 2012-05-25 | Immunostimulatory oligodeoxynucleotides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490387P | 2011-05-26 | 2011-05-26 | |
EP11167605 | 2011-05-26 | ||
PCT/EP2012/059800 WO2012160184A1 (en) | 2011-05-26 | 2012-05-25 | Immunostimulatory oligodeoxynucleotides |
EP12726042.0A EP2714908B1 (en) | 2011-05-26 | 2012-05-25 | Immunostimulatory oligodeoxynucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2714908A1 EP2714908A1 (en) | 2014-04-09 |
EP2714908B1 true EP2714908B1 (en) | 2018-04-18 |
Family
ID=47216636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12726042.0A Active EP2714908B1 (en) | 2011-05-26 | 2012-05-25 | Immunostimulatory oligodeoxynucleotides |
Country Status (12)
Country | Link |
---|---|
US (1) | US9315814B2 (en) |
EP (1) | EP2714908B1 (en) |
JP (1) | JP5872685B2 (en) |
CN (2) | CN103547675A (en) |
BR (1) | BR112013029966A2 (en) |
CA (1) | CA2834440A1 (en) |
MX (1) | MX2013013801A (en) |
PL (1) | PL2714908T3 (en) |
RU (1) | RU2584588C2 (en) |
TR (1) | TR201808393T4 (en) |
WO (1) | WO2012160184A1 (en) |
ZA (1) | ZA201308477B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2471926A3 (en) | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
WO2012160184A1 (en) * | 2011-05-26 | 2012-11-29 | Intervet International B.V. | Immunostimulatory oligodeoxynucleotides |
AR091569A1 (en) * | 2012-06-28 | 2015-02-11 | Intervet Int Bv | TOLL TYPE RECEIVERS |
BR112015030989A2 (en) | 2013-06-14 | 2019-09-24 | Intervet Int Bv | pharmaceutical composition and use of a pharmaceutical composition |
AR097029A1 (en) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE |
EP3200820B1 (en) | 2014-10-03 | 2023-07-05 | Intervet International B.V. | Broad-spectrum vaccine against avian reovirus |
WO2019110481A1 (en) | 2017-12-04 | 2019-06-13 | Intervet International B.V. | Vaccination with replicon particles and oil adjuvant |
CA3085575A1 (en) * | 2017-12-15 | 2019-06-20 | Bayer Animal Health Gmbh | Immunostimulatory oligonucleotides |
CN111542337A (en) | 2017-12-20 | 2020-08-14 | 英特维特国际股份有限公司 | Improved diluents for cell-associated alphaherpesvirus vaccines |
CN110404065B (en) * | 2018-04-27 | 2023-06-16 | 洛阳赛威生物科技有限公司 | Adjuvant composition for pigs and preparation method thereof |
BR112021012167A2 (en) | 2018-12-20 | 2021-08-31 | Intervet International B.V. | INITIAL-REINFORCEMENT VACCINATION SCHEME |
CN110747292A (en) * | 2019-11-28 | 2020-02-04 | 青岛易邦生物工程有限公司 | Method for identifying avian infectious bronchitis QX type virus wild virus and vaccine virus |
WO2021123104A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Multivalent hvt vector vaccine |
CN116648259A (en) | 2020-12-24 | 2023-08-25 | 英特维特国际股份有限公司 | Multivalent HVT Vector Vaccine |
WO2023213946A1 (en) | 2022-05-05 | 2023-11-09 | Intervet International B.V. | New multivalent hvt vector vaccine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO2001055341A2 (en) * | 2000-01-31 | 2001-08-02 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
PT1296713E (en) * | 2000-06-08 | 2004-02-27 | Intercell Biomediz Forschungs | IMMUNOSTIMULATING OLIGODESOXINUCLEOTIDES |
CN1599623B (en) * | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
AU2003247880B2 (en) * | 2002-07-03 | 2010-09-02 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
ATE442376T1 (en) * | 2002-12-23 | 2009-09-15 | Dynavax Tech Corp | OLIGONUCLEOTIDES HAVING AN IMMUNE SYSTEM-STIMULATING SEQUENCE AND METHOD FOR USE THEREOF |
CN1810970B (en) | 2005-01-27 | 2011-05-18 | 长春华普生物技术有限公司 | CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application |
WO2007020017A1 (en) | 2005-08-12 | 2007-02-22 | Bionostra, S.L. | Composition for bird immunization administered by aerosol |
DE102006031483B4 (en) * | 2006-07-07 | 2009-12-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Cellular pyrogen test |
CA2695385A1 (en) | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
JP5343079B2 (en) | 2008-08-18 | 2013-11-13 | 北里第一三共ワクチン株式会社 | Additional immunization method of avian influenza vaccine combined with avian influenza virus antigen and oral mucosal adjuvant effective |
ES2622562T3 (en) | 2008-12-09 | 2017-07-06 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
WO2012160184A1 (en) * | 2011-05-26 | 2012-11-29 | Intervet International B.V. | Immunostimulatory oligodeoxynucleotides |
-
2012
- 2012-05-25 WO PCT/EP2012/059800 patent/WO2012160184A1/en active Application Filing
- 2012-05-25 MX MX2013013801A patent/MX2013013801A/en unknown
- 2012-05-25 PL PL12726042T patent/PL2714908T3/en unknown
- 2012-05-25 RU RU2013156673/10A patent/RU2584588C2/en not_active IP Right Cessation
- 2012-05-25 CN CN201280024814.8A patent/CN103547675A/en active Pending
- 2012-05-25 BR BR112013029966A patent/BR112013029966A2/en not_active IP Right Cessation
- 2012-05-25 TR TR2018/08393T patent/TR201808393T4/en unknown
- 2012-05-25 CA CA2834440A patent/CA2834440A1/en not_active Abandoned
- 2012-05-25 EP EP12726042.0A patent/EP2714908B1/en active Active
- 2012-05-25 JP JP2014511898A patent/JP5872685B2/en not_active Expired - Fee Related
- 2012-05-25 US US14/119,492 patent/US9315814B2/en active Active
- 2012-05-25 CN CN201710789842.3A patent/CN107513533A/en active Pending
-
2013
- 2013-11-11 ZA ZA2013/08477A patent/ZA201308477B/en unknown
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
CA2834440A1 (en) | 2012-11-29 |
WO2012160184A1 (en) | 2012-11-29 |
RU2584588C2 (en) | 2016-05-20 |
US20140193457A1 (en) | 2014-07-10 |
RU2013156673A (en) | 2015-07-10 |
BR112013029966A2 (en) | 2017-01-31 |
JP5872685B2 (en) | 2016-03-01 |
PL2714908T3 (en) | 2018-07-31 |
MX2013013801A (en) | 2013-12-16 |
US9315814B2 (en) | 2016-04-19 |
EP2714908A1 (en) | 2014-04-09 |
JP2014516534A (en) | 2014-07-17 |
CN103547675A (en) | 2014-01-29 |
TR201808393T4 (en) | 2018-07-23 |
ZA201308477B (en) | 2014-08-27 |
CN107513533A (en) | 2017-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2714908B1 (en) | Immunostimulatory oligodeoxynucleotides | |
US9359602B2 (en) | Immunostimulatory oligodeoxynucleotides | |
CA2823065C (en) | Immunostimulatory oligodeoxynucleotides | |
CA2270345C (en) | Immunostimulatory nucleic acid molecules | |
CA2555390A1 (en) | Immunostimulatory viral rna oligonucleotides | |
JP2012517226A (en) | Synthetic RNA-based agonists of TLR7 | |
US10112985B2 (en) | Toll-like receptors | |
SCHRIER et al. | Patent 2823065 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140102 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160617 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SCHRIER, CARLA CHRISTINA Inventor name: ILG, THOMAS SIMON |
|
INTG | Intention to grant announced |
Effective date: 20180123 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012045304 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 990507 Country of ref document: AT Kind code of ref document: T Effective date: 20180515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180718 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180718 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180719 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 990507 Country of ref document: AT Kind code of ref document: T Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180820 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012045304 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 |
|
26N | No opposition filed |
Effective date: 20190121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180418 Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180818 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20220318 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20220414 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220421 Year of fee payment: 11 Ref country code: FR Payment date: 20220422 Year of fee payment: 11 Ref country code: DE Payment date: 20220411 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20220513 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012045304 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20230601 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230601 |